2017 Health for Humanity Report
Better Health for All
Better Health for All
Better Health for All
GRI
Global Reporting Initiative
103-2
The management approach and its components
103-3
Evaluation of the management approach
Better Health for All

World Without Disease

GRI
Global Reporting Initiative
103-2
The management approach and its components
103-3
Evaluation of the management approach

Over the past century, humanity has made considerable progress in reducing the global burden of disease. However, significant gaps remain, and newer challenges, such as antimicrobial resistance and prevalence of chronic diseases, have surfaced with increasing intensity. As a global healthcare leader, Johnson & Johnson is at the forefront of addressing the world’s most intractable diseases. Over the years, our deep, passionate commitment has enabled enormous strides in tackling some of the most complex and pervasive diseases, particularly those that are leading causes of death globally, among them HIV and tuberculosis.

Our R&D efforts are strategically focused on finding transformational solutions that can change the lives of patients in both developed and developing countries. We increasingly take a holistic approach that does not rely solely on treating diseases. We believe it is imperative to address disease along the entire continuum of health, including prevention, disease interceptions and cures. We do so by pooling insights and expertise from across our three business segments to determine the most promising integrated solutions. We also leverage the power of partnerships with leading experts, organizations and patients themselves across the healthcare spectrum, as well as public and private sectors around the world. In fact, we seek to create a world without disease. That is our goal.

More Resources
You are leaving jnj.com and entering a third party site. This link is provided for your convenience, and Johnson & Johnson disclaims liability for content created or maintained by third parties. Continue